Sariya Dinesh, Ruth Karen, Adams-McDonnell Rose, Cusack Carrie, Xu XiaoWei, Elenitsas Rosalie, Seykora John, Pasha Terri, Zhang Paul, Baldassano Marisa, Lessin Stuart R, Wu Hong
Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Arch Dermatol. 2007 May;143(5):613-20. doi: 10.1001/archderm.143.5.613.
To analyze the clinical, histopathologic, and immunohistochemical characteristics of skin metastases.
Retrospective analysis (January 1, 1990, to December 31, 2005).
Comprehensive cancer center.
Fifty-one patients (21 men and 30 women) with biopsy-proven skin metastases and correlative clinical data.
Four dermatopathologists reviewed a random mixture of metastases and primary skin tumors. Immunohistochemical studies for 12 markers were performed on the metastases, with skin adnexal tumors as controls.
Clinical characteristics of cutaneous lesions, clinical outcomes, histologic features, and immunohistochemical markers.
Eighty-six percent (43 of 50) of the patients had known stage IV cancer, and skin metastasis was the presenting sign in 12% (6 of 50). In 45% (21 of 47) of the biopsies, the lesions were not suspected of being metastases owing to unusual clinical presentations. Seventy-six percent of the patients died of disease (median survival, 5 months). On pathologic review, many metastases from adenocarcinomas were either recognized or suspected, but the primary site was not easily identified based on histologic findings alone. Metastases from small cell carcinomas and sarcomas were histologically misinterpreted as primary skin tumors. Immunohistochemical analysis using a panel including p63, B72.3, calretinin, and CK5/6 differentiated metastatic carcinoma from primary skin adnexal tumors.
Cutaneous metastases can have variable clinical appearances and can mimic benign skin lesions. They are usually seen in patients with advanced disease, but they can be the presenting lesion. Although many metastatic adenocarcinomas can be recognized based on histologic findings alone, immunohistochemical analysis is an important diagnostic adjunct in some cases.
分析皮肤转移瘤的临床、组织病理学及免疫组化特征。
回顾性分析(1990年1月1日至2005年12月31日)。
综合癌症中心。
51例经活检证实有皮肤转移瘤且有相关临床资料的患者(21例男性,30例女性)。
4名皮肤病理学家对转移瘤和原发性皮肤肿瘤的随机混合样本进行检查。对转移瘤进行12种标志物的免疫组化研究,以皮肤附属器肿瘤作为对照。
皮肤病变的临床特征、临床结局、组织学特征及免疫组化标志物。
86%(50例中的43例)患者已知患有IV期癌症,皮肤转移是12%(50例中的6例)患者的首发症状。在45%(47例中的21例)活检中,由于临床表现不寻常,病变未被怀疑为转移瘤。76%的患者死于疾病(中位生存期5个月)。经病理检查,许多腺癌转移瘤可被识别或怀疑,但仅根据组织学结果不易确定原发部位。小细胞癌和肉瘤的转移瘤在组织学上被误诊为原发性皮肤肿瘤。使用包括p63、B72.3、钙视网膜蛋白和CK5/6在内的一组标志物进行免疫组化分析,可区分转移性癌和原发性皮肤附属器肿瘤。
皮肤转移瘤临床表现多样,可酷似良性皮肤病变。它们通常见于晚期疾病患者,但也可为首发病变。虽然许多转移性腺癌仅根据组织学结果即可识别,但在某些情况下,免疫组化分析是重要的诊断辅助手段。